Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Morton

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
Pediatric Blood & Cancer|September 1, 2010
Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing ProgramE Anders Kolb, Richard Gorlick, Peter J Houghton, et al.
Journal of Virology|July 30, 2024
rAAV expressing a COBRA-designed influenza hemagglutinin generates a protective and durable adaptive immune response with a single doseKristin B Wiggins, Stephen M Winston, Isaiah L Reeves, et al.
Journal of the National Cancer Institute|May 1, 2015
The role of histone demethylase KDM4B in Myc signaling in neuroblastomaJun Yang, Alaa M AlTahan, Dongli Hu, et al.
Pediatric Blood & Cancer|October 21, 2011
Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing programMalcolm A Smith, John M Maris, Richard Gorlick, et al.
Molecular Therapy. Methods & Clinical Development|February 25, 2022
Preventing packaging of translatable P5-associated DNA contaminants in recombinant AAV vector prepsMark A Brimble, Pei-Hsin Cheng, Stephen M Winston, et al.
Scientific Reports|June 27, 2025
Evolutionary unpredictability in cancer model systemsSubhayan Chattopadhyay, Jenny Karlsson, Michele Ferro, et al.
Pediatric Blood & Cancer|September 17, 2011
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing programMalcolm A Smith, Richard Gorlick, E Anders Kolb, et al.
Molecular Cancer Therapeutics|November 21, 2023
Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome BiogenesisPrahalathan Pichavaram, Carolyn M Jablonowski, Jie Fang, et al.
Pediatric Blood & Cancer|July 12, 2011
Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing programPeter J Houghton, Richard Lock, Hernan Carol, et al.
Molecular Cancer Therapeutics|January 8, 2010
Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing ProgramPeter J Houghton, Christopher L Morton, Richard Gorlick, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Pediatric Blood & Cancer|September 1, 2010
Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing ProgramE Anders Kolb, Richard Gorlick, Peter J Houghton, et al.
Journal of Virology|July 30, 2024
rAAV expressing a COBRA-designed influenza hemagglutinin generates a protective and durable adaptive immune response with a single doseKristin B Wiggins, Stephen M Winston, Isaiah L Reeves, et al.
Journal of the National Cancer Institute|May 1, 2015
The role of histone demethylase KDM4B in Myc signaling in neuroblastomaJun Yang, Alaa M AlTahan, Dongli Hu, et al.
Pediatric Blood & Cancer|October 21, 2011
Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing programMalcolm A Smith, John M Maris, Richard Gorlick, et al.
Molecular Therapy. Methods & Clinical Development|February 25, 2022
Preventing packaging of translatable P5-associated DNA contaminants in recombinant AAV vector prepsMark A Brimble, Pei-Hsin Cheng, Stephen M Winston, et al.
Scientific Reports|June 27, 2025
Evolutionary unpredictability in cancer model systemsSubhayan Chattopadhyay, Jenny Karlsson, Michele Ferro, et al.
Pediatric Blood & Cancer|September 17, 2011
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing programMalcolm A Smith, Richard Gorlick, E Anders Kolb, et al.
Molecular Cancer Therapeutics|November 21, 2023
Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome BiogenesisPrahalathan Pichavaram, Carolyn M Jablonowski, Jie Fang, et al.
Pediatric Blood & Cancer|July 12, 2011
Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing programPeter J Houghton, Richard Lock, Hernan Carol, et al.
Molecular Cancer Therapeutics|January 8, 2010
Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing ProgramPeter J Houghton, Christopher L Morton, Richard Gorlick, et al.
Pageof 10